Biotinylated Human GLP-1R Nanodisc Protein
Catalog No: GLP1R-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His
Product overview
Biotinylated Human GLP-1R Nanodisc Protein is a full-length multi-pass membrane protein presented in a Nanodisc format for antibody discovery, binding assays and method development. Recombinant Biotinylated Human GLP-1R Nanodisc is expressed from HEK293 with His tag at the C-terminus. It contains Met1-Ser463 (accession: P43220).
Product Details
- Molecular Aliases
- GLP-1 receptor; GLP-1-R; GLP-1R; GLP1R
- Protein Length
- Met1-Ser463
- Expression System
- HEK293
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells.
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Aliquot where appropriate and minimize freeze-thaw cycles.
Background
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). GLP-1R emerged as an important pharmacological target for addressing T2DM, as it actively contributes to maintaining glucose homeostasis while promoting both β cell proliferation and insulin release. The impact of GLP-1R agonists such as semaglutide extends beyond diabetes control: they play a multifaceted role in regulating blood glucose levels by reducing hunger, moderating food intake, and managing body weight. Notably, GLP-1R agonists inhibit cancer progression in some malignant tumors.
References
- Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Büsselberg D. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev. 2024 May 27. doi: 10.1007/s10555-024-10192-9. Epub ahead of print. PMID: 38801466.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.